Incidental Uptake of 68 Ga-DOTA-IBA in Prostate Adenocarcinoma.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-28 DOI:10.1097/RLU.0000000000005415

Huipan Liu, Yuhong Liu, Feifan Xiang, Jianwen Zhang, Yue Chen

引用次数: 0

Abstract

Abstract: 68 Ga-labeled DOTA-ibandronic acid ( 68 Ga-DOTA-IBA) is a novel PET agent developed for bone tumors. In addition, 68 Ga-DOTA-IBA uptake in nonosseous findings has also been reported. Herein, we present a case of 68 Ga-DOTA-IBA uptake in primary prostate adenocarcinoma.

查看原文本刊更多论文

前列腺癌对 68Ga-DOTA-IBA 的偶然摄取。

摘要：68Ga标记的DOTA-ibandronic酸（68Ga-DOTA-IBA）是一种新型的正电子发射计算机断层显像剂，用于骨肿瘤。此外，68Ga-DOTA-IBA 在非骨肿瘤中的摄取也有报道。在此，我们介绍一例原发性前列腺腺癌摄取 68Ga-DOTA-IBA 的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.